|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li J, Feng Q, Wei X and Yu Y: MicroRNA-490
regulates lung cancer metastasis by targeting poly r(C)-binding
protein 1. Tumour Biol. 37:15221–15228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ourari-Dhahri B, Ben Slima H, Ben Amar J,
El Gharbi L, Ali M, Azzabi S Baccar, Aouina H and Bouacha H:
Management of non small cell lung cancer. Tunis Med. 90:847–851.
2012.(In French). PubMed/NCBI
|
|
4
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R,
Grannis FW Jr, et al: Non-small cell lung cancer, version 2.2013. J
Natl Compr Canc Netw. 11:645–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zarogoulidis K, Zarogoulidis P, Darwiche
K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N,
Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of
non-small cell lung cancer (NSCLC). J Thorac Dis. 5 Suppl
4:S389–S396. 2013.PubMed/NCBI
|
|
6
|
Ramnath N, Dilling TJ, Harris LJ, Kim AW,
Michaud GC, Balekian AA, Diekemper R, Detterbeck FC and Arenberg
DA: Treatment of stage III non-small cell lung cancer: Diagnosis
and management of lung cancer, 3rd ed: American college of chest
physicians evidence-based clinical practice guidelines. Chest. 143
Suppl 5:e314S–e340S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li C and Hong W: Research status and
funding trends of lung cancer biomarkers. J Thorac Dis. 5:698–705.
2013.PubMed/NCBI
|
|
8
|
Kaplan JA, Liu R, Freedman JD, Padera R,
Schwartz J, Colson YL and Grinstaff MW: Prevention of lung cancer
recurrence using cisplatin-loaded superhydrophobic nanofiber
meshes. Biomaterials. 76:273–281. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kanou T, Okami J, Tokunaga T, Ishida D,
Kuno H and Higashiyama M: Prognostic factors in patients with
postoperative brain recurrence from completely resected non-small
cell lung cancer. Thorac Cancer. 6:38–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Deng XF, Jiang L, Liu QX, Zhou D, Hou B,
Cui K, Min JX and Dai JG: Lymph node micrometastases are associated
with disease recurrence and poor survival for early-stage non-small
cell lung cancer patients: A meta-analysis. J Cardiothorac Surg.
11:282016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hayashita Y, Osada H, Tatematsu Y, Yamada
H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and
Takahashi T: A polycistronic microRNA cluster, miR-17-92, is
overexpressed in human lung cancers and enhances cell
proliferation. Cancer Res. 65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen X, Tong ZK and Zhou JY, Yao YK, Zhang
SM and Zhou JY: MicroRNA-206 inhibits the viability and migration
of human lung adenocarcinoma cells partly by targeting MET. Oncol
Lett. 12:1171–1177. 2016.PubMed/NCBI
|
|
16
|
Lin J, Xu K, Wei J, Heimberger AB, Roth JA
and Ji L: MicroRNA-124 suppresses tumor cell proliferation and
invasion by targeting CD164 signaling pathway in non-small cell
lung cancer. J Gene Ther. 2(pii): 62016.PubMed/NCBI
|
|
17
|
Lin X, Yang Z, Zhang P, Liu Y and Shao G:
miR-154 inhibits migration and invasion of human non-small cell
lung cancer by targeting ZEB2. Oncol Lett. 12:301–306.
2016.PubMed/NCBI
|
|
18
|
Lei T, Zhu Y, Jiang C, Wang Y, Fu J, Fan Z
and Qin H: MicroRNA-320 was downregulated in non-small cell lung
cancer and inhibited cell proliferation, migration and invasion by
targeting fatty acid synthase. Mol Med Rep. 14:1255–1262.
2016.PubMed/NCBI
|
|
19
|
Mou X and Liu S: MiR-485 inhibits
metastasis and EMT of lung adenocarcinoma by targeting Flot2.
Biochem Biophys Res Commun. 477:521–526. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Visone R and Croce CM: MiRNAs and cancer.
Am J Pathol. 174:1131–1138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Zhu W, Zhang J, Huo S, Zhou L, Gu
Z and Zhang M: MicroRNA-650 targets ING4 to promote gastric cancer
tumorigenicity. Biochem Biophys Res Commun. 395:275–280. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun B, Pu B, Chu D, Chu X, Li W and Wei D:
MicroRNA-650 expression in glioma is associated with prognosis of
patients. J Neurooncol. 115:375–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mraz M, Dolezalova D, Plevova K, Kozubik K
Stano, Mayerova V, Cerna K, Musilova K, Tichy B, Pavlova S, Borsky
M, et al: MicroRNA-650 expression is influenced by immunoglobulin
gene rearrangement and affects the biology of chronic lymphocytic
leukemia. Blood. 119:2110–2113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang JY, Cui SY, Chen YT, Song HZ, Huang
GC, Feng B, Sun M, De W, Wang R and Chen LB: MicroRNA-650 was a
prognostic factor in human lung adenocarcinoma and confers the
docetaxel chemoresistance of lung adenocarcinoma cells via
regulating Bcl-2/Bax expression. PLoS One. 8:e726152013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zeng ZL, Li FJ, Gao F, Sun DS and Yao L:
Upregulation of miR-650 is correlated with down-regulation of ING4
and progression of hepatocellular carcinoma. J Surg Oncol.
107:105–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zuo ZH, Yu YP, Ding Y, Liu S, Martin A,
Tseng G and Luo JH: Oncogenic activity of miR-650 in prostate
cancer is mediated by suppression of CSR1 expression. Am J Pathol.
185:1991–1999. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu A, Li J, Wu K, Mo Y, Luo Y, Ye H, Mai
Z, Guo K, Wang Y, Li S, et al: LATS2 as a poor prognostic marker
regulates non-small cell lung cancer invasion by modulating MMPs
expression. Biomed Pharmacother. 82:290–297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yao F, Liu H, Li Z, Zhong C and Fang W:
Down-regulation of LATS2 in non-small cell lung cancer promoted the
growth and motility of cancer cells. Tumour Biol. 36:2049–2057.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yun JH, Moon S, Lee HS, Hwang MY, Kim YJ,
Yu HY, Kim Y, Han BG, Kim BJ and Kim JM: MicroRNA-650 in a copy
number-variable region regulates the production of interleukin 6 in
human osteosarcoma cells. Oncol Lett. 10:2603–2609. 2015.PubMed/NCBI
|
|
31
|
Yabuta N, Fujii T, Copeland NG, Gilbert
DJ, Jenkins NA, Nishiguchi H, Endo Y, Toji S, Tanaka H, Nishimune Y
and Nojima H: Structure, expression, and chromosome mapping of
LATS2, a mammalian homologue of the Drosophila tumor suppressor
gene lats/warts. Genomics. 63:263–270. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang X, Yu J, Yin J, Xiang Q, Tang H and
Lei X: MiR-195 regulates cell apoptosis of human hepatocellular
carcinoma cells by targeting LATS2. Pharmazie. 67:645–651.
2012.PubMed/NCBI
|
|
33
|
Takahashi Y, Miyoshi Y, Morimoto K,
Taguchi T, Tamaki Y and Noguchi S: Low LATS2 mRNA level can predict
favorable response to epirubicin plus cyclophosphamide, but not to
docetaxel, in breast cancers. J Cancer Res Clin Oncol. 133:501–509.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xia Y and Gao Y: MicroRNA-181b promotes
ovarian cancer cell growth and invasion by targeting LATS2. Biochem
Biophys Res Commun. 447:446–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Y, Pei J, Xia H, Ke H, Wang H and Tao
W: Lats2, a putative tumor suppressor, inhibits G1/S transition.
Oncogene. 22:4398–4405. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ke H, Pei J, Ni Z, Xia H, Qi H, Woods T,
Kelekar A and Tao W: Putative tumor suppressor Lats2 induces
apoptosis through downregulation of Bcl-2 and Bcl-x(L). Exp Cell
Res. 298:329–338. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Murakami H, Mizuno T, Taniguchi T, Fujii
M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, et
al: LATS2 is a tumor suppressor gene of malignant mesothelioma.
Cancer Res. 71:873–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang K, Rodriguez-Aznar E, Yabuta N, Owen
RJ, Mingot JM, Nojima H, Nieto MA and Longmore GD: Lats2 kinase
potentiates Snail1 activity by promoting nuclear retention upon
phosphorylation. EMBO J. 31:29–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
